Deutsche Bank AG Purchases Shares of 257,759 ACADIA Pharmaceuticals Inc. $ACAD

Key Points

• Deutsche Bank acquired 257,759 ACADIA Pharmaceuticals shares worth approximately $6.5 million, while several other institutions also opened positions. Institutional investors collectively own 96.71% of the company.
• ACADIA reported quarterly EPS of $0.18, beating estimates of $0.07, while revenue reached $308 million—up 16.4% year over year and above expectations.
• Analysts remain broadly positive, with 14 Buy ratings and three Holds, producing a “Moderate Buy” consensus and an average price target of $34.19. However, insiders sold 36,699 shares worth about $1.02 million over the past 90 days.

Deutsche Bank AG acquired a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 257,759 shares of the biopharmaceutical company's stock, valued at approximately $6,521,000. Deutsche Bank AG owned 0.15% of ACADIA Pharmaceuticals as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Rice Hall James & Associates LLC acquired a new position in shares of ACADIA Pharmaceuticals during the 2nd quarter valued at $15,658,000. Uniting Wealth Partners LLC acquired a new stake in ACADIA Pharmaceuticals in the 2nd quarter valued at $278,000. Global Retirement Partners LLC acquired a new stake in ACADIA Pharmaceuticals in the 2nd quarter valued at $64,000. Bank of New York Mellon Corp purchased a new position in ACADIA Pharmaceuticals in the second quarter valued at about $19,244,000. Finally, State of Wyoming purchased a new position in ACADIA Pharmaceuticals in the second quarter valued at about $1,234,000. Institutional investors and hedge funds own 96.71% of the company's stock.

Insider Activity at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, EVP Elizabeth H.Z. Thompson sold 16,558 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $26.13, for a total transaction of $432,660.54. Following the sale, the executive vice president directly owned 18,994 shares in the company, valued at $496,313.22. The trade was a 46.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mark C. Schneyer sold 14,292 shares of the company's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $29.22, for a total value of $417,612.24. Following the completion of the transaction, the executive vice president directly owned 67,828 shares in the company, valued at approximately $1,981,934.16. The trade was a 17.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 36,699 shares of company stock worth $1,019,894 over the last 90 days. 26.20% of the stock is owned by company insiders.

ACADIA Pharmaceuticals Price Performance

NASDAQ:ACAD opened at $29.65 on Tuesday. The firm has a 50-day moving average of $26.12 and a two-hundred day moving average of $23.50. The stock has a market cap of $5.11 billion, a P/E ratio of 13.36, a PEG ratio of 23.23 and a beta of 0.81. ACADIA Pharmaceuticals Inc. has a 1-year low of $19.69 and a 1-year high of $30.96.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.07 by $0.11. The business had revenue of $308.00 million for the quarter, compared to analyst estimates of $296.55 million. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.The company's revenue for the quarter was up 16.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.16 earnings per share. As a group, equities analysts expect that ACADIA Pharmaceuticals Inc. will post 0.59 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ACAD shares. Citizens Jmp upped their target price on ACADIA Pharmaceuticals from $35.00 to $36.00 and gave the stock a "market outperform" rating in a research report on Wednesday, August 5th. Needham & Company LLC raised their target price on ACADIA Pharmaceuticals from $38.00 to $41.00 and gave the company a "buy" rating in a report on Wednesday, August 12th. Citigroup boosted their price target on ACADIA Pharmaceuticals from $35.00 to $39.00 and gave the stock a "buy" rating in a research report on Monday, August 10th. Weiss Ratings upgraded ACADIA Pharmaceuticals from a "hold (c)" rating to a "hold (c+)" rating in a report on Wednesday, August 12th. Finally, Canaccord Genuity Group increased their price objective on shares of ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a "buy" rating in a research report on Monday, June 29th. Fourteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $34.19.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company's flagship product, NUPLAZID® (pimavanserin), received U.S.

Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source